Mikhail Blagosklonny is a professor of oncology at the Rosewell Park Cancer Institute in Buffalo, New York. Mikhail Blagosklonny is also a skilled researcher and dedicated philanthropist committed to making the best medical care available to all individuals irregardless of socioeconomic status.Mikhail Blagosklonny has committed much of his life’s work to the research of cancer and aging. More specifically, Dr. Blagosklonny is interested in the connection between the two and the reasons cancer is more prevalent in individuals who have advanced past certain ages. One of his most important contributions to his field of expertise so far is the research he has done on the drug Rapamycin and his subsequent advocacy of the cancer drug’s potential to prolong the life span of the human being.Rapamycin, also known by the name Sirolimus is a pharmaceutical initially used to prevent the rejection of transplanted organs. The drug has also been used to coat coronary stents and the treatment of a rare lung disease. But these uses have proven to be only transparent scratches to the surface in regards to the full scope of Rapamycin’s potential uses:
Superior Immunosuppressant Properties
The body’s natural reaction to organ transplants is to reject the new organ. To prevent this outcome drugs known as Immunosuppressants are prescriptive protocol. Often times these drugs prove detrimental to kidney function. Rapamycin scores well here as the drug has proven to be less toxic to kidneys than other immunosuppressants.
Best Treatment For Patients With Hemolytic-Uremic Syndrome
Hemolytic-Uremic Syndrome is a rare disease caused by the combined effects of anemia, kidney failure, and a low platelet count. This often results in major renal failure. The only options for patients at this point is a lifetime of dialysis or kidney transplantation. When opting for transplants there is a considerable chance that transplanted kidneys will also develop the same disease. Rapamycin greatly lowers this risk.
Used To Treat Lymphangioleiomyomatosis
LAM is a rare disease that usually affects women of childbearing age. Rapamycin has been identified as the primary drug to cure this disease.
Rapamycin is ripe with antiproliferative properties and improves immune response to tumors in the body. Rapamycin has also been proven to promote tumor regression as well. These qualities are reasons the drug is of great use to cancer patients who have had organ transplants.
Increased Life Span Of The Individual
Dr. Mikhail Blagosklonny has completed a considerable amount of research on the potential of Rapamycin to increase human life span. The drug has proven to increase the ability of aging mice to deal with the effects of tuberculosis. Human testing have shown that Rapamycin has the ability to improve immunological rejuvenation in elderly persons when given prior to an influenza vaccination. Though his research has not yet yielded conclusive results, Dr. Mikhail Blagosklonny is in fact convinced that Rapamycin will be proven to to increase the life span of human beings.
Through its parent journal, Impact Journals, Oncotarget publishes scientific research findings on oncology and other medical-related fields every week. Since it published its first article seven years ago, the journal has gone ahead to publish thousands of other insightful and peer-reviewed articles. All the articles are in English, which makes them readable by a huge population across the world. Besides that, Oncotarget is categorized under open-access journals, meaning that anyone interested in scientific knowledge has a fair chance of accessing it in the journal.
The team behind Oncotarget is not only qualified and dedicated but also talented and with an impressive research record. Led by chief editors, Prof. Andrei V. Gudkov and his counterpart Prof. Mikhail Blagoskloklonny, the team ensures that the articles circulated in the journal meet the threshold of high quality and exhaustively informational. The chief editors are renowned professors at Roswell Park Cancer Institute in Buffalo, New York.Blagosklonny has authored more than 250 articles in peer-reviewed journals. Andrei Gudkov, on the other hand, has made an immense contribution to the study of cancer therapies, particularly in drug discovery and molecular targets.
The Impact Factor
In its first year of publication, Oncotarget recorded an impact factor (IF) of 4.78 and was being received by readers across 493 cities, which was impressive for a new entrant. A year later, the reception had increased to 1450 cities, and its IF had risen to 6.636. 2013 is the year when Oncotarget registered the highest impact factor, recording a 6.627. In the same year, the number of cities receiving the journal rose to over 2200 cities. The following year, the journal had an IF of 6.359, a drop but still consistently high. The reception at this time was almost hitting 4,000 cities. Today, the impact factor for Oncotarget stands at 5.168 while the reception has grown to more than 30,000 cities. Comparatively, Oncotarget’s reception has multiplied by almost 100 times over the seven years of its existence.
Source of the article : http://gettingstronger.org/tag/mikhail-blagosklonny/
Eric Lefkofsky is an individual who has done many things in his life to enhance the lives of the individuals around him. Eric Lefkofsky is founder of Tempus. Tempus is a medical technology company like no other. The focus of Tempus is to help physicians to give personalize cancer care to their patients. Tempus is known as a health technology company.
Tempus is able to deliver analytical information about molecular structure of its patient’s. This is known as genomic sequencing. This genomic sequencing is able to give highly valuable data to a physician. This is data that helps the physician to make decisions about the type of therapy that is going to work best for their patients. Since each and every patient has a different genetic makeup, it stands to reason that the best treatment for each patient will be different as well.
The goal that Tempus is to deliver a treatment plan that will better benefit the patients by giving doctors the tools that they need to gather the most complete information about their patient’s. Apart from creating Tempus, Eric Lefkofsky has been able to help create many companies as well. Some of his more known companies are the following: Uptake, Groupon, Mediaocean, and Lightbank.
Eric Lefkofsky is an individual who truly cares about the well-being of others. He strives to improve lives of the communities in which he lives, and he also endeavors to help individuals on an international platform as well. Eric Lefkofsky and his wife Liz founded The Lefkofsky Foundation. The Lefkofsky Foundation is a foundation that gives to different causes around the world. Their goal is to enhance the lives of individuals by providing them with the tools that they need to develop a love of art and education. This foundation also works with hospitals around the world. These are causes that the Lefkofsky’s hold very near and dear to their heart, and that is why they decided to make a foundation.
Eric Lefkofsky is an individual who has used his wealth to better the lives of others, and he continues to enhance his portfolio when it comes to philanthropy and technology.
To know more visit @: lefkofskyfoundation.com/about-eric-lefkofsky/